Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- Active Versus Passive Shipping Solutions For Clinical Shipments
- January 2026 — CDMO Opportunities And Threats Report
- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Challenges, Methods, And Solutions For Obtaining Optimal Starting Material
For innovative treatments like CAR-T and stem cell transplants, optimal starting material is key. Understanding collection challenges and new solutions helps ensure the best foundation for these therapies.
-
Comparison Of Single-Use And Steel Fermentors For Malaria Vaccine Production
Support the advancement of malaria vaccine development by leveraging innovative bioprocessing solutions to enable efficient, scalable, and accessible vaccine production worldwide.
-
AAV Viral Titering Using Nanoplate-Based Digital PCR
Examine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.
-
Single-Use Innovation For The Future Of Therapeutic Manufacturing
Gain insight into these end-to-end plasmid DNA solutions, leveraging robust cGMP-compliant processes and single-use manufacturing platforms to accelerate your cell and gene therapy programs.
-
Partnering With Health Systems: Essential Tips For CGT Commercialization
Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Preparing For Disease X: Effective Vaccine Development In The Face Of A Future Pandemic
CDMOs are playing a critical role in the global effort to prepare for future pandemics. Learn how innovative strategies and flexible platforms are helping to ensure a swift and effective response plan.
-
Residual Plasmid Quantification In Gene Therapy Manufacturing Workflows
This article details the design and application of a Plasmid DNA - Kanamycin Resistance Gene (pDNA-KanR) kit for residual plasmid quantification in gene therapy manufacturing.
-
Anaerobic Cultivation Processes Of Probiotic Bacteria
Cultivate oxygen-sensitive probiotics with precision using real-time monitoring, microfluidic feeding, and pH control for reproducible growth and optimized microbiome and fermentation research.
-
The Importance Of Quality Proteins For Research, Development, And Manufacturing
Learn how validated testing, strict sourcing, and regulatory guidance help minimize endotoxin contamination risks and support reliable therapeutic development in advanced medicinal products.
NEWSLETTER ARCHIVE
- 02.20.26 -- Deciding When Research Grade Raw Materials Are Sufficient
- 02.19.26 -- Advancing Your Cell and Gene Therapy Journey
- 02.19.26 -- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- 02.18.26 -- Specialized Fill/Finish For Advanced Therapies
- 02.18.26 -- Cold-Chain Packaging Strategies For Scaling Gene Therapies
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections